Lilly's breast cancer drug succeeds in late-stage study

Eli Lilly and Co said on Tuesday that its breast cancer therapy Verzenio met the main goal of reducing the risk of it returning in the early stages in a late-stage study, sending its shares up 8.5% in pre-market trade.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news